United Therapeutics Corp.

Address: 55 Tw Alexander Drive, P. O. Box 14186

Sponsor Overview

assignment

Specializations

Fibrotic lung disease and idiopathic pulmonary fibrosis

United Therapeutics Corp. supports clinical research in fibrotic lung disease, with particular attention to idiopathic pulmonary fibrosis and related interstitial lung disease presentations. Its studies focus on inhaled therapies used in chronic pulmonary fibrosis settings and on outcomes relevant to lung function and disease progression.

Inhaled treprostinil
Forced vital capacity
Progressive pulmonary fibrosis

The sponsor’s trial portfolio includes multinational research across multiple sites in North America, Europe, and other active regions.

Pulmonary arterial hypertension

The company also funds studies in pulmonary arterial hypertension (PAH), where the therapeutic emphasis includes vascular-targeted treatment and long-term disease management. Research activity in this area addresses clinical worsening, symptom burden, and sustained treatment use in affected patients.

Ralinepag
Clinical worsening
Pulmonary vascular disease

These studies involve collaborative work with a broad network of research sites and ongoing recruitment across several countries.

Long-term safety and tolerability research

A substantial part of the sponsor’s clinical program is devoted to extended evaluation of treatment safety and tolerability in chronic pulmonary disorders. This includes follow-up research for patients with IPF, PPF, and PAH, reflecting sustained interest in therapies used over long periods.

Open-label extension studies
Chronic respiratory disease
Maintenance therapy

The sponsor’s funded trials span multiple therapeutic settings, linking fibrotic lung disease management with vascular lung disease care.

Sponsored Trials

Trial Name	Country	Status
Evaluation of Ralinepag Efficacy and Safety in Pulmonary Arterial Hypertension: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial	Austria Belgium Bulgaria Czechia Denmark France Germany Greece Hungary Italy Poland Portugal Romania Spain The Netherlands	Not Recruiting
Long-term Safety and Efficacy Evaluation of Ralinepag in Pulmonary Arterial Hypertension: An Open-label Extension Study	Austria Belgium Bulgaria Czechia Denmark France Germany Greece Hungary Italy Poland Portugal Romania Spain The Netherlands	Not Recruiting
Long-term Safety and Tolerability Evaluation of Inhaled Treprostinil in Patients with Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis	Belgium Denmark France Germany Italy Spain The Netherlands	Recruiting
Phase 3 Multinational, Randomized, Double-blind, Placebo-controlled Study on Inhaled Treprostinil Efficacy and Safety in Idiopathic Pulmonary Fibrosis	Belgium Denmark France Germany Italy Spain The Netherlands	Not Recruiting
Phase 3 Randomized, Double-blind, Placebo-controlled Study of Inhaled Treprostinil in Progressive Pulmonary Fibrosis Patients	Belgium France Germany Italy Spain	Recruiting